OncoSec Medical Incorporated (NASDAQ:ONCS) issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.05), Yahoo Finance reports.
Shares of OncoSec Medical (ONCS) traded up $0.17 on Friday, reaching $2.26. 9,225,200 shares of the company were exchanged, compared to its average volume of 748,818. OncoSec Medical has a twelve month low of $0.88 and a twelve month high of $2.55.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/12/oncosec-medical-incorporated-oncs-posts-earnings-results-misses-estimates-by-0-05-eps.html.
ONCS has been the topic of several recent research reports. Maxim Group reiterated a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a research note on Tuesday, October 10th. ValuEngine upgraded shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of OncoSec Medical in a research note on Thursday. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $5.33.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.